Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (221-230 of 459) with videos related to

Pageof 46
Sort By:
International Journal of Cancer|December 16, 2025
Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)"Javier Molina-Cerrillo, Giandomenico Roviello, Ondrej Fiala, et al.
International Journal of Cancer|December 3, 2013
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, et al.
Journal of Nephrology|November 22, 2015
Transplantation of kidneys with tumorsGiovanni M Frascà, Antonia D'Errico, Deborah Malvi, et al.
Frontiers in Oncology|April 27, 2019
Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future ChallengesMatteo Santoni, Alessia Cimadamore, Liang Cheng, et al.
European Urology Focus|November 2, 2020
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular PerspectivesYang Zong, Rodolfo Montironi, Francesco Massari, et al.
Cancer Treatment Reviews|February 2, 2016
AR-V7 and prostate cancer: The watershed for treatment selection?Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, et al.
Critical Reviews in Oncology/Hematology|March 2, 2026
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinomaSebastiano Buti, Betty Dalla Valle, Alessandro Acunzo, et al.
Cancer Treatment Reviews|June 4, 2015
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic targetMatteo Santoni, Kalliopi Andrikou, Valeria Sotte, et al.
Human Vaccines & Immunotherapeutics|December 19, 2024
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changesElisa Tassinari, Linda Danielli, Andrea Marchetti, et al.
The International Journal of Biological Markers|June 26, 2015
HER family receptor expression and prognosis in pancreatic cancerAlessandro Bittoni, Alessandra Mandolesi, Kalliopi Andrikou, et al.
Pageof 46

Showing results (221-230 of 459) with videos related to

Sort By:
Pageof 46
International Journal of Cancer|December 16, 2025
Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)"Javier Molina-Cerrillo, Giandomenico Roviello, Ondrej Fiala, et al.
International Journal of Cancer|December 3, 2013
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, et al.
Journal of Nephrology|November 22, 2015
Transplantation of kidneys with tumorsGiovanni M Frascà, Antonia D'Errico, Deborah Malvi, et al.
Frontiers in Oncology|April 27, 2019
Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future ChallengesMatteo Santoni, Alessia Cimadamore, Liang Cheng, et al.
European Urology Focus|November 2, 2020
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular PerspectivesYang Zong, Rodolfo Montironi, Francesco Massari, et al.
Cancer Treatment Reviews|February 2, 2016
AR-V7 and prostate cancer: The watershed for treatment selection?Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, et al.
Critical Reviews in Oncology/Hematology|March 2, 2026
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinomaSebastiano Buti, Betty Dalla Valle, Alessandro Acunzo, et al.
Cancer Treatment Reviews|June 4, 2015
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic targetMatteo Santoni, Kalliopi Andrikou, Valeria Sotte, et al.
Human Vaccines & Immunotherapeutics|December 19, 2024
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changesElisa Tassinari, Linda Danielli, Andrea Marchetti, et al.
The International Journal of Biological Markers|June 26, 2015
HER family receptor expression and prognosis in pancreatic cancerAlessandro Bittoni, Alessandra Mandolesi, Kalliopi Andrikou, et al.
Pageof 46